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license (http://creativenegative predictive values of an Alzheimer’s disease (AD) blood test if implemented in primary care.
Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-
based, and clinic-based cohorts were analyzed. A “locked-down” referent group of 1128 samples was
generated with 201 samples randomly selected for validation purposes. Random forest analyses were
used to create theADblood screen. Positive (PPV) and negative (NPV) predictive valueswere calculated.
Results: In detecting AD, PPVwas 0.81, and NPVwas 0.95 while using the full AD blood test.When
detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary
analyses were conducted to detect any “neurodegenerative disease”. The full 21-protein AD blood
test yielded a PPVof 0.85 and NPVof 0.94.
Discussion: The present study creates the first-ever multiethnic referent sample that spans
community-based and clinic-based populations for implementation of an AD blood screen.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Primary care; Blood test; Screening; Diagnosis; Predictive power1. Introduction
Alzheimer’s disease (AD) is the most common dementia
and is the fifth leading cause of death for those over 65 years
[1]. Currently, over 5 million Americans suffer from AD [2],
and it is estimated that those numbers will grow exponen-
tially by 2050. AD has an annual health care cost similar
to that of cardiovascular disease and more than cancer [3].
As a result of these rapidly increasing numbers, there is a
growing need for the identification of a time-effective and
cost-effective screening tool for use in primary care settings.uthor. Tel.: 11-(817)-735-2963; Fax: 11-(817)-735-
d.O’Bryant@unthsc.edu
16/j.dadm.2016.06.004
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).The Centers forMedicare andMedicaid Services recently
implemented the annual wellness visit (AWV) that includes
a cognitive examination (CMS.gov); however, the 2015
American Gerontological Society working group reported
that “older adults are inadequately assessed for cognitive
impairment during routine visits with their primary care pro-
viders” [4]. This limited access to early diagnostics has been
associated with delayed treatment initiation, delays in provi-
sion of services to family members, overall decreased qual-
ity of life, and increased family burden [5]. Given the limited
time available in primary care visits (average of 18 minutes),
primary care providers are left with a significant dilemma of
how to meet the AWV requirements.
In our prior work, we have proposed that an AD blood test
could serve as the first stage in a multi-stage diagnosticimer’s Association. This is an open access article under the CC BY-NC-ND
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S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 83-9084workup [6] as is the case in infectious disease, cancer, and
cardiovascular disease. A blood test can fit into the current
infrastructure and be used to rule out patients who do not
need further workup. We hypothesize that a blood-based
screening tool for AD [7–10] can serve as the first step in
a multistage detection process [11] within community-
based clinics. Obtaining an early diagnosis within primary
care settings can increase access to current therapies, reduce
overall health care costs [12], delay nursing home placement
[13], facilitate a connection with community resources, and
reduce caregiver stress [13] as well as assist in future plan-
ning [13]. This model follows the evolution of breast cancer
screening in primary care [13].
When designing a biomarker (blood based or otherwise),
it is crucial to first define the context of use and outline the
methods for development per that fit-for-purpose [14–16]
as well as outline the minimum performance requirements
of the biomarker itself. In this case, what is the overall
purpose of the AD blood screener when applied to a
primary care setting? Is it to “diagnose” AD or to
determine who needs follow-up examination? In primary
care settings (and other settings), a key context of use for
nearly all screening tests is to rule out those who do not
have the disease to decrease the numbers of patients that un-
dergo more invasive and costly procedures. For example,
mammography does not rule in breast cancer as the positive
predictive values (PPV) are below 30% [17,18].
Additionally, screening of depression in primary care has
low PPVs (e.g., 0.15–0.27) [19], but negative predictive po-
wer is excellent (.0.96) [19]. In both cases, the screening
test ensures that only thosewho need the follow-up examina-
tion (biopsy, psychiatric referral) undergo such procedures,
which serves as cost containment and reduces unnecessary
medical services to patients. This strategy also provides a
streamlined, step-wise process for physicians to make deci-
sions regarding which tests are used in what order.
Therefore, it is our proposal that a primary care AD blood
screen can be used to rule out 85% or more of elderly pa-
tients seen in primary care who do not need to undergo
more expensive procedures. Therefore, a screen positive
on the AD blood test would trigger a multistage neurodiag-
nostic process of (1) neurology specialty exam for differen-
tial purposes, (2) cognitive testing, and finally, (3)
cerebrospinal fluid analysis and/or PET amyloid imaging.
When moving from discovery to clinical consideration of
biomarkers, there are a series of steps for validation purposes
[20]. Once the biomarker has been identified and initial vali-
dation studies have been conducted (independent of the dis-
covery set), the methods must be “locked down” for
additional prospective studies (e.g., clinical trials) [20].
This “lock-down” procedure is where all steps in the process
are solidified and no longer available for further manipula-
tion. With regard to multimarker algorithm applications,
such as our AD blood test, this includes the generation of
a locked-down referent sample to which all future blood
samples are compared. To date, no work globally has created
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 83-90 85such a locked-down referent sample, which is required for
the next step of a clinical trial of the AD blood screen specif-
ically within primary care settings. In this study, by
leveraging samples and data across numerous clinic-based
and community-based cohorts, we generated the first-ever
locked-down referent sample for an AD blood screen and
conducted a preliminary validation of this referent sample.
Additionally, estimates of positive and negative predictive
values were calculated simulating primary care setting
base rates. To consider cost containment, analyses were con-
ducted for a 10-protein version of the algorithm in addition
to the full 21-protein algorithm that has been established
in our prior work [6].Table 2
Breakdown of final “locked-down” referent sample by diagnosis
Diagnosis Sample size
Normal cognition 722
Mild cognitive impairment 307
Alzheimer’s disease 300
Total sample 13292. Methods
2.1. Participants
Blood proteomic data were analyzed from 1329 individ-
uals across multiple community-based and clinic-based co-
horts outlined below. Table 1 contains the demographic
characteristics of each cohort.
2.1.1. Health & Aging Brain among Latino Elders
Samples were analyzed from the Health & Aging Brain
among Latino Elders (HABLE) study, an ongoing epidemi-
ologic study of cognitive aging among community-
dwelling Mexican Americans and non-Hispanic whites
[21,22]. The HABLE study uses a community-based
participatory research approach, which involves partnering
communities to conduct studies of human disease. This
research was conducted under an institutional review board
approved protocol with each participant (and/or infor-
mants for cognitively impaired persons) providing written
informed consent. Each participant underwent an inter-
view (i.e., medical history, medications, and health behav-
iors), detailed neuropsychological testing, blood draw, and
medical examination (review of systems, Hachinski
Ischemic Index scale, brief neurological screen). Testing
was completed in English or Spanish depending on the par-
ticipant’s preference. Consensus diagnoses were assigned
according to published criteria [23,24].
2.1.2. UTSW—Alzheimer’s Disease Center
Samples from the NIA-funded UTSW-ADC bio-
repository were analyzed. Each participant underwent an
interview, neuropsychological testing, blood draw, and med-
ical examination per the NACC protocol. Consensus diag-
nosis was assigned based on published criteria [23–27].
Samples were drawn from both clinic-based and
community-based subjects from prior ADC work.
2.1.3. Mayo Clinic—Jacksonville Alzheimer’s Disease
Center
Clinic-based samples were assayed from the NIA-funded
Mayo Clinic Jacksonville ADC biorepository. Eachparticipant underwent an interview, neuropsychological
testing, blood draw, and medical examination per the
NACC protocol. Consensus diagnosis was assigned based
on published criteria [23–27].
2.1.4. Panama Aging Research Initiative study [28]
Samples were assayed from community-based partici-
pants from the Panama Aging Research Initiative (PARI)
cohort, the first-ever study of Panamanian aging. PARI par-
ticipants were recruited from the outpatient geriatric ser-
vices from the largest public hospital of the social security
located in Panama. Each participant underwent an interview,
neuropsychological testing, and blood draw. All participants
(or their proxies) signed informed consent forms, and patient
confidentiality was not breached in accordance with the
Declaration of Helsinki (1964). Consensus diagnosis was as-
signed according to published criteria [23,24].
2.2. Sample collection
UTSW-ADC, Mayo, and PARI samples were collected
nonfasting, whereas HABLE samples were collected fast-
ing. Serum—(1) serum samples were collected into 10-mL
tiger-top tubes; (2) samples were allowed to clot for 30 mi-
nutes at room temperature in a vertical position; (3) samples
were centrifuged for 10 minutes at 1300! g at room temper-
ature within 1 hour of collection; (4) 1.0-mL aliquots were
transferred into cryovial tubes; and (5) samples were placed
into 280 C freezers for storage until use. Plasma—(1)
blood was collected into 10-mL lavender-top tubes and
gently inverted 10–12 times; (2) tubes were centrifuged at
1300! g at room temperature for 10 minutes within 1
hour of collection; (3) 1-mL aliquots were transferred to
cryovial tubes; and (4) tubes were placed in280C freezers
for storage. Table 2 provides the breakdown of blood sam-
ples by diagnosis. Table 3 provides descriptive statistics
for the individual proteomic markers assayed.
2.3. Proteomic assays
Proteomic data were obtained in duplicate via a multiplex
biomarker assay platform using electrochemiluminescence
on the SECTOR Imager 2400A from MSD (available at
http://www.mesoscale.com). The MSD platform has been
used extensively to assay biomarkers associated with a range
of human diseases including AD. In our prior work, we con-
ducted discovery and validation studies to identify and refine
a putative AD blood profile. In our most recent work [6], we
Table 3
Descriptive statistics of the proteomic markers assayed
Total
Mean (SD)
Range
AD
Mean (SD)
Range
MCI
Mean (SD)
Range
Normal control
Mean (SD)
Range LLOD range
A2M pg/mL 2,207,345,434
(726,174,209.6)
122,991.2–
7,206,174,358
2,259,607,984
(604,654,494.3)
146,894.0–
4,542,176,487
2,229,140,420
(831,608,551.4)
280,762.9–
7,206,174,358
2,119,302,013
(637,895,357.6)
853,628,046.9–
5,511,893,404
0.908–0.958
B2M pg/mL 2,390,617.9 (1,272,067)
0–18,045,940.0
2,460,678.7 (1,123,022.5)
105–9,799,050.5
2,348,623.8 (1,211,847.8)
0–14,355,126.7
2,234,756.8 (1,063,833.6)
792,827.1–17,914,318.7
6.1
CRP pg/mL 846,864.7 (2,857,127.7)
0–34,466,996.7
742,972.9 (3,144,226.5)
73.1–33,929,332.0
1,173,191.1 (2,997,816.7)
40.9–22,954,496.7
602,395.9 (2,272,422.7)
36.9–24,661,007.0
0.69–19.8
Eotaxin 3 pg/mL 14.9 (174.6)
0–6117.0
19.6 (292.0)
0–6117.0
23.8 (184.2)
0–3055.8
6.1 (22.9)
0–407.0
1.29–4.13
FABP ng/mL 66,067.2 (61,188.4)
0–669,094.2
52,850.6 (59,117.6)
679.4–346,447.1
105,976.6 (63,600.9)
13,985.0–408,764.7
61,480.8 (54,688.9)
1339.9–669,094.2
0.0952–0.107
FVII pg/mL 1,057,670.6 (390,333.5)
0–3,079,368.0
948,151.9 (325,428.8)
3580.9–2,535,543.1
1,112,188.9 (409,878.2)
0–2,500,304.8
1,079,483.0 (365,270.0)
121,001.3–2,901,171.2
3.44–4.32
I309 pg/mL 4.9 (5.3)
0–85.4
4.4 (5.3)
0–85.4
6.0 (5.0)
0.5–36.1
5.0 (5.5)
0.1–48.4
0.408–0.46
IL10 pg/mL 8.7 (54.9)
0–933.3
5.1 (29.0)
0.1–528.1
9.6 (53.2)
0–690.0
10.7 (67.2)
0.1–933.3
0.01–0.15
IL18 pg/mL 264.4 (168.0)
0–1996.2
224.6 (124.6)
33.1–965.1
296.8 (192.4)
47.1–1366.9
271.6 (173.2)
12.6–1996.2
0.71
IL5 pg/mL 1.6 (10.4)
0–229.7
1.6 (11.7)
0–229.7
0.9 (1.1)
0.1–10.5
1.8 (11.2)
0–200.4
0.05–0.56
IL6 pg/mL 3.9 (32.8)
0–1296.1
7.1 (63.1)
0.2–1296.1
3.5 (11.4)
0.2–173.8
2.5 (3.3)
0.1–56.5
0.01–0.11
IL7 pg/mL 10.1 (8.7)
0–70.6
9.8 (6.2)
0–40.6
13.9 (11.9)
0.1–70.6
9.9 (8.7)
0–63.7
0.11–0.57
MIP1-a pg/mL 288.6 (1663.0)
0–43,165.7
267.4 (1057.0)
0–11,224.8
277.8 (1320.5)
12.3–20,077.5
357.6 (2170.3)
0–43,165.7
2.28–4.01
PPY pg/mL 922.4 (718.6)
0–5948.5
769.0 (630.1)
0–5948.5
1258.0 (763.7)
0–3767.7
921.8 (707.4)
0–3889.6
68
SAA pg/mL 2,008,947.1 (11,394,948.1)
0–268,920,684.1
1,570,719.8 (7,092,494.0)
217.2–76,765,892.5
1,389,405.3 (3,822,218.7)
263.2–39,870,868.6
1,489,218.3 (9,981,282.1)
3.7–168,188,978.4
1.07–35.5
sICAM1 pg/mL 93,923.5 (207,907.0)
0–2,028,774.2
72,355.4 (176,827.9)
128.1–1,053,408.2
140,460.6 (265,191.1)
136.7–1,953,128.9
68,741.3 (175,030.4)
104.1–962,580.7
0.46–14.4
sVCAM1 pg/mL 139,452.9 (301,075.4)
0–2,263,171.5
109,219.4 (271,034.9)
227.3–2,149,384.1
187,033.9 (326,444.2)
149.4–1,711,980.5
102,407.2 (264,527.0)
62.8–2,263,171.5
0.93–35.8
TARC pg/mL 441.4 (545.5)
12.8–7944.6
527.2 (549.4)
18.7–3783.5
415.1 (408.3)
28.4–2507.7
392.2 (479.9)
15.9–6867.9
0.17–0.54
Thrombopoietin pg/mL 756.1 (429.4)
0–3906
657.8 (306.6)
147.7–3822.7
921.2 (507.8)
174.3–2546.7
738.8 (420.3)
96.9–3906.9
19
TNC pg/mL 43,394.1 (18,901.8)
0–187,278.8
44,560.2 (16,727.2)
1822.4–128,344.8
46,704.2 (23,407.6)
0–187,278.8
40,826.4 (16,991.4)
11,475.1–1,583,594.5
0.44–0.47
TNFa pg/mL 3.1 (2.4)
0–37.9
3.4 (3.2)
0.5–37.9
4.3 (2.1)
0.4–21.1
2.7 (1.8)
0–14.3
0.01–0.13
Abbreviations: LLOD, lowest level of detection; SAA, serum amyloid A; FABP, fatty acid binding protein; CRP, c-reactive protein; TNC, tenascin C; sVCAM1,
soluble vascular cell-adhesion molecule-1; sICAM1, soluble intercellular cell-adhesion molecule-1; PPY, pancreatic polypeptide; TNF, tumor necrosis factor.
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 83-9086refined the AD algorithm to 21-proteins, validated the algo-
rithm on an independent assay platform technology, and
validated the algorithm across species and tissue type [6].
Additionally, this 21-protein AD algorithm retains excellent
diagnostic accuracy across ethnic groups. Therefore, this
study sought to create the locked-down referent sample for
the full 21-protein AD blood screen [6]: fatty acid binding
protein (FABP), beta 2 microglobulin, pancreatic polypep-
tide, macrophage inflammatory protein 1a (MIP1a), c-reac-
tive protein (CRP), soluble vascular cell-adhesion molecule-
1 (sVCAM-1), thrombopoietin, a2 macroglobulin, eotaxin3, tumor necrosis factor-alpha (TNF-a), tenascin C,
interleukin-5 (IL-5), IL-6, IL-7, IL-10, IL-18, I309, Factor
VII, thymus and activation-regulated chemokine, serum am-
yloid A, and soluble intercellular cell-adhesion molecule-1.2.4. Statistical analyses
Analyses were performed using IBM SPSS21 and R. Chi
square and t tests were used to compare case versus controls
for categorical variables (sex and race) and continuous vari-
ables (age and education), respectively. Per the Institute of
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 83-90 87Medicine (IOM) guidelines [20], we created a “locked-
down” referent sample of n 5 1128 samples. To do this, a
random sample of n 5 201 samples was selected from the
full sample of n 5 1329 for initial validation of the referent
cohort. The remaining sample of 1128 samples was com-
bined into a single-referent sample. Once validation studies
were completed, the full existing sample (n 5 1329) be-
comes the complete “locked-down” referent sample for all
future clinical trials and community-based projects looking
at this AD blood screen. This locked-down referent sample
is multi-ethnic, community-based and clinic-based and
covers a broad age spectrum as is needed for implementation
of a validated biomarker algorithm [14,15]. Sensitivity,
specificity, and area under the receiver operating
characteristic curve (AUC) were generated from the
random forest analyses. It has been estimated previously
that approximately 12% of individuals age 65 years and
above suffer from AD [2] (i.e., the estimated population
base rate). Therefore, approximately 12% of all older adults
age 65 years and above being seen in primary care settings
are suffering fromAD. Therefore, PPVand NPVwere calcu-
lated for AD using Bayesian statistics [29] using the esti-
mated population base rate of 12% of AD among those
age 65 years and above.3. Results
Table 1 provides the demographic characteristics of the
sample. The referent “locked-down” sample (n5 1128; con-
trol, n 5 613; AD, n 5 255; mild cognitive impairment
[MCI], n5 260) was used to detect AD among the validation
sample (n 5 201; control, n 5 109; AD, n 5 45; MCI,
n 5 47). Applying the AD blood screen from the “locked-
down” referent sample, the 21-protein algorithm yielded
an AUC was of 0.87. The addition of age, gender, and edu-
cation improved the AUC to 0.89. Therefore, PPVand NPV
were calculated using the full algorithm of 21-
proteins 1 demographics (age, gender, and education).
Holding specificity (SP) at 0.98, sensitivity (SN) was 0.63
which resulted in a PPVof 0.81 and NPVof 0.95. In an effort
to consider cost reduction and scalability, we restricted the
AD blood test to only the top 10 proteomic
markers 1 demographics. The overall AUC was 0.90.
When holding SP 5 .98, SN fell to 0.58, which resulted in
a PPV 5 0.80 and NPV 5 0.95.
Next, the referent “locked-down” samplewas used to detect
MCI. Using the full 21-protein algorithm1 demographics, the
AUC was 0.88. With SP set to 0.98, SN was 0.42 which
yielded a PPV 5 0.74 and NPV 5 0.93. When restricted
only to the 10-protein 1 demographics algorithm, the AUC
was to 0.89. With SP set at 0.98, SN was 0.45, which resulted
in a PPV 5 0.75 and NPV 5 0.93.
Finally, preliminary analyses were conducted to deter-
mine the accuracy of the AD blood screen at detecting any
neurodegenerative disease (Parkinson’s disease [PD,
n=53], Lewy Body Dementia [LBD, n=53], Down syndrome[DS n=19], AD vs NC) using samples from the ADCs. Using
the 21-protein 1 demographics AD blood test, the overall
AUC was 0.92. Setting SP 5 0.98, SN was 0.62. Using a
15% base rate of any neurodegenerative disease, PPV was
0.85 and NPV 5 0.94 for detecting any neurodegenerative
disease. Using the top 10 proteins 1 demographics, the
AUC was 0.89. Holding SP 5 0.95, SN was 0.40 which re-
sulted in a PPV 5 0.59 and NPV 5 0.90.4. Discussion
These results provide the first-ever locked-down referent
sample and proof-of-concept support for the potential utility
of our AD blood test as a primary care assessment tool to
determine which patients warrant follow-up examination.
As noted above, the context of use for this test is not diag-
nostic, but rather to provide a tool for assisting primary
care physicians in making an empirically based judgment
on who requires a referral for more costly and invasive pro-
cedures. The availability of such a tool for primary care pro-
viders would serve to increase access to specialty clinics,
cerebrospinal fluid biomarker analysis and amyloid PET
scans by reducing the numbers of inappropriate referrals.
The AD blood screen provided an excellent NPV (0.95)
and PPV (0.80) for detecting AD. In fact, the AD blood test
outperformedmany screening instruments currently available
for primary care. The AD blood screen was also excellent in
ruling out MCI (NPV 5 0.93), and PPV was also very good
(0.75). Given that the AD blood test was built for the context
of use (COU) as a primary care screening tool for AD, this
lower PPV is not surprising. However, when applied to
MCI, the AD blood screen still performed comparable to or
better than many commonly used primary care screens.
Table 4 provides an overview of a broad range of
screening tools for various conditions for comparison pur-
poses. This table is intended to put the current work into
context of existing tools and to set appropriate estimated per-
formance parameters for this specific COU. For example, the
15-item Geriatric Depression Scale yields a PPV5 0.15 and
NPV 5 0.99 for screening depression in a primary care
setting [19] when appropriate base rates are applied [38].
The CES-D provided a PPV5 0.27 and NPV5 1.0 for ma-
jor depression and PPV 5 0.10 and NPV 5 0.96 for minor
depression [19]. Urine dipstick in an emergency room
screening setting for detecting diabetic ketoacidosis yields
a PPV 5 0.15 but NPV 5 0.99. G-FOBT provides a
PPV5 0.35 and NPV5 0.99 for detecting colorectal cancer
[34]. Low-dose computed tomography for lung-cancer
screening provides a PPV 5 0.42 and NPV 5 0.99. PSA
has a poor PPV but excellent NPV [30]. Capillary blood
glucose only has a PPVof 0.20 for detecting gestational dia-
betes but a NPV of 0.95 [31]. As seen in Table 4, a host of
screening instruments provide excellent NPV and therefore
these initial screening tests rule out a tremendous number
of patients who do not need subsequent examinations that
are more invasive and costly. Therefore, our AD blood
Table 4
Positive (PPV) and negative (NPV) predictive values of screening tests used in primary care and other settings
Screening test PPV NPV Context of use
Breast cancer
Mammography [18] 0.19–0.29 Not provided Breast cancer screening in primary care
Digital mammography [17] 0.12 Not provided Breast cancer screening in primary care
Geriatric depression
GDS-15 [19] 0.15 0.99 Depression screening in primary care
CES-D major dep [19] 0.27 1.0 Depression screening in primary care
CES-D minor dep [19] 0.10 0.96 Depression screening in primary care
Prostate cancer
PSA [30] 0.06 0.97 Prostate cancer screening and treatment monitoring
Gestational diabetes
Capillary blood glucose [31] 0.20 0.95 Screening for gestational diabetes
Hypertension
Blood pressure testing [32] 0.35–0.95 OBPM screening for hypertension as confirmed by ABPM or HBPM
Diabetic ketoacidosis
Urine dipstick [33] 0.15 0.99 Emergency department screening of diabetic ketoacidosis in hyperglycemic patients
B-OHB [33] 0.35 0.99
Colorectal cancer
G-FOBT [34] 0.35 0.99 Colorectal Ca screening within hospital settings
FIT [34] 0.11 0.99 Colorectal Ca screening within hospital settings
CT colonography [35] 0.62–0.92 0.79–0.97 Follow-up colorectal cancer assessment with positive FOBT when colonoscopy is not available
HIV
HIV screening [36] 0.10 0.99 Screening HIV in older children in primary care in high HIV prevalence settings
Lung cancer
Low-dose CT [37] 0.42 0.99 Screening for lunch cancer with low-dose CT
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able estimated parameters for the intended COU, and the
next step in this work is to conduct prospective studies
(e.g., clinical trials) leveraging the current locked-down
referent sample.
In addition to serving as a means for primary care
screening, the AD blood test also has a tremendous advan-
tage for increasing access to disease-modifying drugs (clin-
ical trials and medications when Food and Drug
Administration [FDA] approved). Specifically, the AD blood
screen can be used to rule out those who should not undergo
PET amyloid imaging for inclusion into clinical trials or
consideration for treatment once FDA approval is acquired
for one of these drugs. PET amyloid scanning is expensive
and, as with cancer, not a viable first line in determining
drug intervention. If our AD blood screen provides a
NPV 5 0.90 with a PPV 5 0.70, this would reduce the
PET amyloid scanning needs significantly. For example, us-
ing the MCI results above with SP 5 0.98 and SN 5 0.42,
PPV 5 0.74 and NPV 5 0.93. If a total of 10,000 patients
were screened for eligibility to PET scans (for clinical trial
entry or drug administration), PET amyloid screening costs
would be approximately $50 million at $5000 per scan
(less than the anticipated clinical cost of this scan). If the
AD blood test were used as the first step, it could accurately
rule out 8642 adults from receiving PET scans and reduce
the PET scan screening cost by over $43 million. Again,
the key purpose is to rule out those who do not need a
PET scan.
Availability of this AD blood screen would result in a sig-
nificant cost savings of the screening budget for clinicaltrials and a cost savings when considering incorporating
disease-modifying drugs into clinical practice. Given that in-
surance companies do not pay for the FDA-approved amy-
loid scanning methods, the availability of this AD blood
screen could also be used to build a successful reimburse-
ment strategy for amyloid PET scans for those who screen
positive on the blood test (i.e., cost containment). This model
for seeking reimbursement can follow what has been suc-
cessful in the cancer space. For example, more expensive
imaging modalities such as PET scans for breast cancer
only became reimbursed by CMS as an adjunct to other im-
aging modalities (that are less expensive) rather than the
first-line or standalone procedure [39]. The comparative
effectiveness research in the cancer space [40–42] could
help outline a landscape for seeking approval and
reimbursement for screening and diagnostic testing in AD
in anticipation of the availability of disease-modifying
agents in the near future. Therefore, the availability of the
AD blood test could provide a cost-effective method for im-
plementation of disease-modifying drugs into the current
medical system.
Overall, the current findings are supportive of further
investigation into the current AD blood screen as a tool for
primary care physicians and a clinical trial should be con-
ducted. This tool is intended to refine the diagnostic process
such that those who screen positive undergo additional steps
for the diagnosis and differential diagnosis. This process can
also streamline and maximize cost-effectiveness of PETam-
yloid scans once disease-modifying drugs become FDA
approved. Fig. 1 provides an example of an updated patient
flow diagram for the multistage neurodiagnostic workup and
Primary Care - blood screen
CogniƟve tesƟng
a. PET amyloid scan 
or 
b. Lumbar puncture for assay of biomarkers of 
neurodegeneraƟon (amyloid, tau, α-synuclein, 
NfL)
DemenƟa Specialist
Fig. 1. Multistate diagnostic process for detecting Alzheimer’s disease
(AD) and discriminating AD from other dementias.
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AD and non-AD dementias.
When put into the context of the IOM guidelines for steps
from discovery to clinical utility, the AD blood test is ready
for a full-scale clinical trial within the context of use of pri-
mary care settings. Additional lock-down steps would be
required if the AD blood screen is to be reduced in size
(e.g., 5-proteins rather than 21 or even 10). Additional
lock-down work should be conducted to maximize the blood
collection protocols to ensure global scalability of the
methods. The current work establishes the “locked-down”
reference sample for the first-ever clinical trial of an AD
blood test in primary care.5. Conclusion
The current findings suggest that an AD blood test for pri-
mary care settings is a viable option for a cost-effective and
time-effective means of making determinations as to which
patients require follow-up examinations and procedures, and
a clinical trial is required to demonstrate the prospective
diagnostic accuracy. Provision of this AD blood screen could
increase access to currently available medications and re-
sources. Additionally, the availability of an AD primary
care assessment tool would increase access to more
advanced diagnostic procedures (CSF or imaging bio-
markers) as well as disease-modifying drugs, once available.
Our AD blood screen performs equivalent to or better than
many primary care screening examinations. The current
work is poised for the first-ever clinical trial of an AD blood
test in primary care, which is required for validation of this
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1. Systematic review: To date, there is no blood
screening tool for primary care providers to determine
which patients should be referred for more expensive
and invasive diagnostic procedures. Such a screening
test would meet the annual wellness visit (AWV)
requirements and increase appropriate access to
advanced diagnostic procedures (imaging, cerebro-
spinal fluid, clinical) as well as disease-modifying
medications, once FDA approval has been achieved.
2. Interpretation: Data were combined across multiple
clinic-based and community-based cohorts to
generate a multi-ethnic “locked-down” referent
cohort for the AD blood screen. Diagnostic accuracy,
positive and negative predictive power, was excellent
for the AD blood screen.
3. Future directions: With the availability of the locked-
down referent cohort, the first-ever clinical trial of an
AD blood screen in primary care clinics can be
conducted. Additionally, the utility of this blood-
screen as the first step in the diagnostic process for
PET scans should be examined as this would
significantly decrease costs and increase access to
disease-modifying agents once FDA approval is ob-
tained.
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